Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of patupilone every 3 weeks in advanced non-small cell lung cancer
2004-004252-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patupilone in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Overall response rate. Started Aug 2005; status: completed.
02
Drugs
patupilone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-004252-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004252-40.